ILARIS^®—Complete Response

Complete Response From Cryopyrin-Associated Periodic Syndromes (CAPS) Within the First Dosing Period (8 Weeks)*

• 97% of CAPS patients treated with ILARIS® (canakinumab) achieved complete response within 8 weeks^1,2
• The majority of CAPS patients treated with ILARIS® (71%) achieved complete response in just 7 days^1,2
• Normalized serum amyloid A (SAA) and C-reactive protein (CRP) levels^1,2
• Complete response was defined as ratings of minimal or absent for physician's assessment of disease activity and assessment of skin disease and C-reactive protein (CRP) or serum amyloid A (SAA) values <10 mg/L^1,2

*The pivotal study included an 8-week, open-label period (Part 1) and a 24-week, randomized, double-blind, placebo-controlled withdrawal period (Part 2).^1,2